• 1
    Arends, M.J. & Wyllie, A.H. (1991) Apoptosis: mechanisms and roles in pathology. International Reviews of Experimental Pathology, 32, 223 254.
  • 2
    Banner, D.W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H.J., Broger, C., Loetscher, H., Lesslauer, W. (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell, 73, 431 435.
  • 3
    Barak, Y., Juven, T., Haffner, R., Oren, M. (1993) mdm2 expression is induced by wild type p53 activity. EMBO Journal, 12, 461 468.
  • 4
    Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R., Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189 199.
  • 5
    Ben-Yehuda, D., Krichevsky, S., Caspi, O., Rund, D., Polliack, A., Abeliovich, D., Zelig, O., Yahalom, V., Paltiel, O., Or, R., Peretz, T., Ben-Neriah, S., Yehuda, O., Rachmilewitz, E.A. (1996) Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood, 88, 4296 4303.
  • 6
    Bissonnette, R.P., Echeverri, F., Mahboubi, A., Green, D.R. (1992) Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature, 359, 552 554.
  • 7
    Bogdanovic, A.D., Trpinac, D.P., Jankovic, G.M., Bumbasirevic, V.Z., Obradovic, M., Colovic, M.D. (1997) Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia, 11, 656 659.
  • 8
    Boldin, M.P., Goncharov, T.M., Goltsev, Y.V., Wallach, D. (1996) Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell, 85, 803 815.
  • 9
    Bouscary, D., De Vos, J., Guesnu, M., Jondeau, K., Viguier, F., Melle, J., Picard, F., Dreyfus, F., Fontenay-Roupie, M. (1997) Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia, 11, 839 845.
  • 10
    Bowen, D., Yancik, S., Bennett, L., Culligan, D., Resser, K. (1993) Serum stem cell factor concentration in patients with myelodysplastic syndromes. British Journal of Haematology, 85, 63 66.
  • 11
    Bradbury, D.A., Zhu, Y.M., Russell, N.H. (1997) Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leukemia and Lymphoma, 24, 221 228.
  • 12
    Bueso-Ramos, C.E., Yang, Y., DeLeon, E., McCown, P., Stass, S.A., Albitar, M. (1993) The human MDM-2 oncogene is overexpressed in leukemias. Blood, 82, 2617 2623.
  • 13
    Campos, L., Rouault, J.P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J.P., Guyotat, D. (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091 3096.
  • 14
    Chinnaiyan, A.M., O'Rourke, K., Lane, B.R., Dixit, V.M. (1997) Interaction of CED-4 with CED-3 and CED-9: a molecular framework for cell death. Science, 275, 1122 1126.
  • 15
    Chinnaiyan, A.M., O'Rourke, K., Tewari, M., Dixit, V.M. (1995) FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell, 81, 505 512.
  • 16
    Clark, D.M. & Lampert, I.A. (1990) Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective haematopoiesis. Leukemia and Lymphoma, 2, 415 418.
  • 17
    Coutinho, L.H., Geary, C.G., Chang, J., Harrison, C., Testa, N.G. (1990) Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). British Journal of Haematology, 75, 16 25.
  • 18
    Delia, D., Aiello, A., Soligo, D., Fontanella, E., Melani, C., Pezzella, F., Pierotti, M.A., Della-Porta, G. (1992) bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood, 79, 1291 1298.
  • 19
    El Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817 825.
  • 20
    Enari, M., Talanian, R.V., Wong, W.W., Nagata, S. (1996) Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature, 380, 723 726.
  • 21
    Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Land, H., Brooks, M., Waters, C.M., Penn, L.Z., Hancock, D.C. (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69, 119 128.
  • 22
    Fakharzadeh, S.S., Trusko, S.P., George, D.L. (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO Journal, 10,1565 1569.
  • 23
    Finlay, C.A. (1993) The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Molecular Cell Biology, 13, 301 306.
  • 24
    Fisher, G.H., Rosenberg, F.J., Straus, S.E., Dale, J.K., Middleton, L.A., Lin, A.Y., Strober, W., Lenardo, M.J., Puck, J.M. (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell, 81, 935 946.
  • 25
    Friesen, C., Herr, I., Krammer, P.H., Debatin, K.M. (1996) Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukaemia cells. Nature Medicine, 2, 574 577.
  • 26
    Gersuk, G.M., Yamaguchi, M., Beckham, C., Kiener, P., Anderson, J.E., Trout, T., Loken, M.R., Deeg, H.J. (1996) A role for fas, fas-ligand and TNF-α in the dysregulation of hematopoiesis in myelodysplastic syndrome (MDS). Blood, 88, 639a.
  • 27
    Grana, X. & Reddy, E.P. (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11, 211 219.
  • 28
    Greenberg, P.L., Ginzton, N., Rajapaksa, R., Tong, C.R., Han, J.H. (1994) Apoptosis in myelodysplastic syndrome (MDS). Blood, 84, 159a.
  • 29
    Harbour, J.W., Lai, S.L., Whang-Peng, J., Gazdar, A.F., Minna, J.D., Kaye, F.J. (1988) Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science, 241, 353 357.
  • 30
    Harrington, E.A., Bennett, M.R., Fanidi, A., Evan, G.I. (1994) c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO Journal, 13, 3286 3295.
  • 31
    Hatta, Y., Hirama, T., Miller, C.W., Yamada, Y., Tomonaga, M., Koeffler, H.P. (1995) Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood, 85, 2699 2704.
  • 32
    Helin, K., Harlow, E., Fattaey, A. (1993) Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Molecular Cell Biology, 13, 6501 6508.
  • 33
    Hellstrom-Lindberg, E., Kanter-Lewensohn, L., Ost, A. (1997) Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leukemia Research, 21, 415 425.
  • 34
    Hirama, T. & Koeffler, H.P. (1995) Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood, 86, 841 854.
  • 35
    Hsu, H., Huang, J., Shu, H.B., Baichwal, V., Goeddel, D.V. (1996) TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity, 4, 387 396.
  • 36
    Hsu, H., Xiong, J., Goeddel, D.V. (1995) The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell, 81, 495 504.
  • 37
    Hu, Z.B., Minden, M.D., McCulloch, E.A. (1996) Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy. Leukemia, 10, 410 416.
  • 38
    Itoh, N. & Nagata, S. (1993) A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. Journal of Biological Chemistry, 268, 10932 10937.
  • 39
    Jacobson, M.D., Burne, J.F., King, M.P., Miyashita, T., Reed, J.C., Raff, M.C. (1993) Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature, 361, 365 369.
  • 40
    Jiang, W., Zhang, Y.J., Kahn, S.M., Hollstein, M.C., Santella, R.M., Lu, S.H., Harris, C.C., Montesano, R., Weinstein, I.B. (1993) Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proceedings of the National Academy of Sciences of the United States of America, 90, 9026 9030.
  • 41
    Johnson, D.G., Schwarz, J.K., Cress, W.D., Nevins, J.R. (1993) Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature, 365, 349 352.
  • 42
    Johnson, E.M., Chen, P.L., Krachmarov, C.P., Barr, M., Kanovsky, M., Ma, Z.W., Lee, W.H. (1995) Association of human Pur alpha with the retinoblastoma protein, Rb, regulates binding to the single-stranded DNA Pur alpha recognition element. Journal of Biological Chemistry, 270, 24352 24360.
  • 43
    Jonveaux, P., Fenaux, P., Quiquandon, I., Pignon, J.M., Lai, J.L., Loucheux-Lefebvre, M.H., Goossens, M., Bauters, F., Berger, R. (1991) Mutations in the p53 gene in myelodysplastic syndromes. Oncogene, 6, 2243 2247.
  • 44
    Kato, J., Matsushime, H., Hiebert, S.W., Ewen, M.E., Sherr, C.J. (1993) Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes and Development, 7, 331 342.
  • 45
    Kitagawa, M., Yoshida, S., Kuwata, T., Tanizawa, T., Kamiyama, R. (1994) p53 expression in myeloid cells of myelodysplastic syndromes: association with evolution of overt leukemia. American Journal of Pathology, 145, 338 344.
  • 46
    Kornblau, S.M., Xu, H.J., Zhang, W., Hu, S.X., Beran, M., Smith, T.L., Hester, J., Estey, E., Benedict, W.F., Deisseroth, A.B. (1994) Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood, 84, 256 261.
  • 47
    Kuhl, J.S., Krajewski, S., Duran, G.E., Reed, J.C., Sikic, B.I. (1997) Spontaneous overexpression of the long form of the bcl-X protein in a highly resistant P388 leukaemia. British Journal of Cancer, 75, 268 274.
  • 48
    Lai, J.L., Preudhomme, C., Zandecki, M., Flactif, M., Vanrumbeke, M., Lepelley, P., Wattel, E., Fenaux, P. (1995) Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion: an entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia, 9, 370 381.
  • 49
    Lam, M., Dubyak, G., Chen, L., Nunez, G., Miesfeld, R.L., Distelhorst, C.W. (1994) Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proceedings of the National Academy of Sciences of the United States of America, 91, 6569 6573.
  • 50
    Landowski, T.H., Gleason-Guzman, M.C., Dalton, W.S. (1997) Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood, 89, 1854 1861.
  • 51
    Lezon-Geyda, K.A., Najfeld, V., Johnson, EM. (1997) Deletion of the PURA gene encoding the single-stranded DNA-binding protein PURa, in myelodysplastic syndome (MDS) and myeloid leukemias. Leukemia Research, 21, S36.
  • 52
    Lin, D., Shields, M.T., Ullrich, S.J., Appella, E., Mercer, W.E. (1992) Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proceedings of the National Academy of Sciences of the United States of America, 89, 9210 9214.
  • 53
    Linette, G.P., Li, Y., Roth, K., Korsmeyer, S.J. (1996) Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proceedings of the National Academy of Sciences of the United States of America, 93, 9545 9552.
  • 54
    Liu, X., Kim, C.N., Yang, J., Jemmerson, R., Wang, X. (1996) Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell, 86, 147 157.
  • 55
    Ma, Z.W., Pejovic, T., Najfeld, V., Ward, D.C., Johnson, E.M. (1995) Localization of PURA, the gene encoding the sequence-specific single-stranded-DNA-binding protein Pur alpha, to chromosome band 5q31. Cytogenetics and Cell Genetics, 71, 64 66.
  • 56
    Maciejewski, J., Selleri, C., Anderson, S., Young, N.S. (1995a) Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood, 85, 3183 3196.
  • 57
    Maciejewski, J.P., Selleri, C., Sato, T., Anderson, S., Young, N.S. (1995b) Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. British Journal of Haematology, 91, 245 252.
  • 58
    Marsh, J.C., Chang, J., Testa, N.G., Hows, J.M., Dexter, T.M. (1991) In vitro assessment of marrow ‘stem cell’ and stromal cell function in aplastic anaemia. British Journal of Haematology, 78, 258 267.
  • 59
    Mashal, R., Shtalrid, M., Talpaz, M., Kantarjian, H., Smith, L., Beran, M., Cork, A., Trujillo, J., Gutterman, J., Deisseroth, A. (1990) Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood, 75, 180 189.
  • 60
    Maurer, A.B., Ganser, A., Buhl, R., Seipelt, G., Ottmann, O.G., Mentzel, U., Geissler, R.G., Hoelzer, D. (1993) Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia, 7, 1728 1733.
  • 61
    Min, Y.H., Lee, S., Lee, J.W., Chong, S.Y., Hahn, J.S., Ko, Y.W. (1996) Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy. British Journal of Haematology, 93, 928 930.
  • 62
    Minn, A.J., Velez, P., Schendel, SL., Liang, H., Muchmore, S.W., Fesik, S.W., Fill, M., Thompson, C.B. (1997) Bcl-x(L) forms an ion channel in synthetic lipid membranes. Nature, 385, 353 357.
  • 63
    Miyashita, T., Krajewski, S., Krajewska, M., Wang, H.G., Lin, H.K., Liebermann, D.A., Hoffman, B., Reed, J.C. (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799 1805.
  • 64
    Muchmore, S.W., Sattler, M., Liang, H., Meadows, R.P., Harlan, J.E., Yoon, H.S., Nettesheim, D., Chang, B.S., Thompson, C.B., Wong, S.L., Ng, S.L., Fesik, S.W. (1996) X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature, 381, 335 341.
  • 65
    Mufti, G.J. & Galton, D.A. (1986) Myelodysplastic syndromes: natural history and features of prognostic importance. Clinical Haematology, 15, 953 971.
  • 66
    Musto, P., Matera, R., Minervini, M.M., Checchia de Ambrosio, C., Bodenizza, C., Falcone, A., Carotenuto, M. (1994) Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin. Haematologica, 79, 265 268.
  • 67
    Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E., Dixit, V.M. (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death–inducing signaling complex. Cell, 85, 817 827.
  • 68
    Nagata, S. & Golstein, P. (1995) The Fas death factor. Science, 267, 1449 1456.
  • 69
    Nakamaki, T., Bartram, C., Seriu, T., Kahan, J., Fukuchi, K., Tsuruoka, N., Janssen, J.W.G., Miller, C.W., Koeffler, H.P. (1997) Molecular analysis of the cyclin-dependent kinase inhibitor genes, p15, p16, p18 and p19 in the myelodysplastic syndromes. Leukemia Research, 21, 235 240.
  • 70
    Nakamaki, T., Kawamata, N., Schwaller, J., Tobler, A., Fey, M., Pakkala, S., Lee, Y.Y., Kim, B.K., Fukuchi, K., Tsuruoka, N., Kahan, J., Miller, C.W., Koeffler, H.P. (1995) Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. British Journal of Haematology, 91, 139 149.
  • 71
    Naumovski, L. & Cleary, M.L. (1996) The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Molecular Cell Biology, 16, 3884 3892.
  • 72
    Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L., Vogelstein, B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80 83.
  • 73
    Oltvai, Z.N., Milliman, C.L., Korsmeyer, S.J. (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609 619.
  • 74
    Owen-Schaub, L.B., Zhang, W., Cusack, J.C., Angelo, L.S., Santee, S.M., Fujiwara, T., Roth, J.A., Deisseroth, A.B., Zhang, W.W., Kruzel, E., Radinsky, R. (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Molecular Cell Biology, 15, 3032 3040.
  • 75
    Paquette, R.L., Landaw, E.M., Pierre, R.V., Kahan, J., Lubbert, M., Lazcano, O., Isaac, G., McCormick, F., Koeffler, H.P. (1993) N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood, 82, 590 599.
  • 76
    Parker, J.E., Fishlock, K.L., Mijovic, A., Pagliuca, A., Mufti., G.J. (1997) Leukemic progression in myelodysplastic syndromes (MDS) is associated with decreased apoptosis and a reduced ratio of pro- versus anti-apoptotic Bcl-2 related proteins. Blood, 90, 520a.
  • 77
    Ponce-Castaneda, M.V., Lee, M.H., Latres, E., Polyak, K., Lacombe, L., Montgomery, K., Mathew, S., Krauter, K., Sheinfeld, J., Massague, J., Cordoncardo, C. (1995) p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Research, 55, 1211 1214.
  • 78
    Preudhomme, C., Quesnel, B., Vachee, A., Lepelley, P., Collyn D'Hooghe, M., Wattel, E., Fenaux, P. (1993) Absence of amplification of MDM2 gene, a regulator of p53 function, in myelodysplastic syndromes. Leukemia, 7, 1291 1293.
  • 79
    Preudhomme, C., Vachee, A., Lepelley, P., Vanrumbeke, M., Zandecki, M., Quesnel, B., Cosson, A., Fenaux, P. (1994) Inactivation of the retinoblastoma gene appears to be very uncommon in myelodysplastic syndromes. British Journal of Haematology, 87, 61 67.
  • 80
    Quesnel, B., Preudhomme, C., Oscier, D., Lepelley, P., Collyn d'Hooghe, M., Facon, T., Zandecki, M., Fenaux, P. (1994) Over-expression of the MDM2 gene is found in some cases of haematological malignancies. British Journal of Haematology, 88, 415 418.
  • 81
    Rajapaksa, R., Ginzton, N., Rott, L.S., Greenberg, P.L. (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 88, 4275 4287.
  • 82
    Raza, A., Gezer, S., Gregory, S.A., Venugopal, P., Kaizer, H., Dong, L.M., Span, L., Hines, C., Thomas, R., Alvi, S., Mundle, S.D., Shetty, V., Borok, R., Loew, J., Reza, S., Robin, E.L., Rifkin, S.D., Alston, D., Hernandez, B.M., Shah, R., Hsu, W.T., Dar, S., Preisler, H.D. (1996a) Anti-cytokine therapy produces responses in patients with myelodysplastic syndromes (MDS). Blood, 88, 580a.
  • 83
    Raza, A., Gezer, S., Mundle, S., Gao, X.Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J., Marcus, B., Khan, Z., Chaney, C., Showel, J., Gregory, S., Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268 276.
  • 84
    Raza, A., Mundle, S., Shetty, V., Alvi, S., Chopra, H., Span, L., Parcharidou, A., Dar, S., Venugopal, P., Borok, R., Gezer, S., Showel, J., Loew, J., Robin, E., Rifkin, S., Alston, D., Hernandez, B., Shah, R., Kaizer, H., Gregory, S. (1996b) Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. International Journal of Hematology, 63, 265 278.
  • 85
    Reed, J.C. (1997) Double identity for proteins of the Bcl-2 family. Nature, 387, 773 776.
  • 86
    Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I.A., Debatin, K.M., Fischer, A., De Villartay, J.P. (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science, 268, 1347 1349.
  • 87
    Saito, M., Helin, K., Valentine, M.B., Griffith, B.B., Willman, C.L., Harlow, E., Look, A.T. (1995) Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics, 25, 130 138.
  • 88
    Schendel, S.L., Xie, Z.H., Montal, M.O., Matsuyama, S., Montal, M., Reed, J.C. (1997) Channel formation by antiapoptotic protein Bcl-2. Proceedings of the National Academy of Sciences of the United States of America, 94, 5113 5118.
  • 89
    Sherr, C.J. (1993) Mammalian G1 cyclins. Cell, 73, 1059 1065.
  • 90
    Shibasaki, F., Kondo, E., Akagi, T., McKeon, F. (1997) Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature, 386, 728 731.
  • 91
    Shibasaki, F. & McKeon, F. (1995) Calcineurin functions in Ca(2+)-activated cell death in mammalian cells. Journal of Cell Biology, 131, 735 743.
  • 92
    Shiohara, M., El Deiry, W.S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D.L., Vogelstein, B., Koeffler, H.P. (1994) Absence of WAF1 mutations in a variety of human malignancies. Blood, 84, 3781 3784.
  • 93
    Silverman, L.R., Zinzar, S., Holland, J.F. (1997) Biological consequences of stromal abnormalities in the myelodysplastic syndrome (MDS): its influence on the hematopoietic dysregulation. Leukemia Research, 21, S20.
  • 94
    Stoetzer, O.J., Nussler, V., Darsow, M., Gullis, E., Pelka-Fleischer, R., Scheel, U., Wilmanns, W. (1996) Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia, 10, S18 S22.
  • 95
    Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y., Hirai, H. (1993) Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood, 81, 3022 3026.
  • 96
    Tewari, M., Quan, L.T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D.R., Poirier, G.G., Salvesen, G.S., Dixit, V.M. (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell, 81, 801 809.
  • 97
    Tsoplou, P. & Zoumbos, N. (1996) Programmed cell death in the marrow of patients with myelodysplastic and myeloproliferative diseases concerns almost exclusively CD34+ cells. Blood, 88, 95a.
  • 98
    Tsujimoto, Y., Cossman, J., Jaffe, E., Croce, C.M. (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science, 228, 1440 1443.
  • 99
    Verhoef, G.E., De Schouwer, P., Ceuppens, J.L., Van Damme, J., Goossens, W., Boogaerts, M.A. (1992) Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia, 6, 1268 1272.
  • 100
    Visani, G., Zauli, G., Tosi, P., Fogli, M., Cenacchi, A., Finelli, C., Gamberi, B., Ottaviani, E., Manfoi, S., Tura, S. (1993) Impairment of GM-CSF production in myelodysplastic syndromes. British Journal of Haematology, 84, 227 231.
  • 101
    Wang, H.G., Rapp, U.R., Reed, J.C. (1996) Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell, 87, 629 638.
  • 102
    Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., Fenaux, P. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148 3157.
  • 103
    Williams, G.T., Smith, C.A., Spooncer, E., Dexter, T.M., Taylor, D.R. (1990) Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature, 343, 76 79.
  • 104
    Yang, E. & Korsmeyer, S.J. (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88, 386 401.
  • 105
    Yang, J., Liu, X., Bhalla, K., Kim, C.N., Ibrado, A.M., Cai, J., Peng, T.I., Jones, D.P., Wang, X. (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science, 275, 1129 1132.
  • 106
    Yoshida, Y. (1993) Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia, 7, 144 146.
  • 107
    Zhu, Y.M., Bradbury, D.A., Keith, F.J., Russell, N. (1994) Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia, 8, 1982 1988.
  • 108
    Zou, H., Henzel, W.J., Liu, X.S., Lutschg, A., Wang, X.D. (1997) Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90, 405 413.